Alzheimer’s decline diminished 54 per cent in main new drug trial
Doctors say it works a bit like a gene ‘off-switch’
A leading charity has welcomed the clinical trial results of a new drug to combat Alzheimer’s disease as “very encouraging”. In a major trial, patients given low-dose diranersen injections showed 54% less decline on a test of memory and thinking over almost two years, according to the Telegraph.
Alzheimer’s happens when the proteins amyloid and tau abnormally build up in the brain. The treatment shows a reduction in tau, the newspaper added, saying it uses gene-silencing technology to tackle disease at its source, blocking the RNA messages that tell brain cells to produce tau.
Dr Richard Oakley, associate director for research and innovation at Alzheimer’s Society, said of the CELIA trial results announced at clinical trials on Alzheimer’s disease in Boston: “Alzheimer’s is a complex disease, but we know that the build-up of two proteins in the brain, amyloid and tau, plays an important role in its development.
“While many recent scientific advances have focused on amyloid, we urgently need treatments that tackle Alzheimer’s in different ways. Diranersen is a particularly interesting therapy because it targets tau at its source.
“It works a bit like a gene ‘off-switch’, reducing the amount of tau the brain produces rather than trying to clear it once it has already built up. The treatment is given via lumbar puncture into the fluid around the spinal cord.
“The latest clinical trial results for this drug are very encouraging. They suggest that diranersen effectively reduces the build-up of tau in the brain, and the treatment’s ability to slow worsening of memory and thinking problems increases over two years. If these promising findings are confirmed in the upcoming phase three trial, a significant new treatment option for early Alzheimer’s disease could be within touching distance.
“Research is making huge progress and will beat dementia – and as more potential treatments emerge, it’s more important than ever that people get an early and accurate dementia diagnosis so they can benefit from them. We look forward to seeing the full results from this trial and how this drug progresses.”
British patients are asking to join the next trial, with UK recruitment expected to start in the spring, the Telegraph said.



